Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective

Metabolic dysfunction-associated steatohepatitis (MASH) is emerging as a leading cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality worldwide. Among the most advanced pharmacologic candidates are resmetirom, a highly liver-selective thyroid hormone receptor-β (THR-β) agonist,...

Descrición completa

Detalles Bibliográficos

Autor Principal:	Ralf Weiskirchen
Formato:	Artigo
Idioma:	Inglês
Publicado:	Open Exploration 2025-10-01
Series:	Exploration of Drug Science
Assuntos:	masld therapy drugs thyroid hormone receptor-β agonist glp-1 receptor agonist
Acceso en liña:	https://www.explorationpub.com/uploads/Article/A1008132/1008132.pdf
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!